Turkey (Türkiye)
-
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers
Phase 2 · 220 people · 55 sites in 13 countries · Recruiting now
-
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Phase 2 · randomised · 302 people · 109 sites in 22 countries · Running, not taking new patients
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now
-
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now
-
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Phase 3 · randomised · 990 people · 281 sites in 26 countries · Recruiting now
-
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer
Phase 3 · randomised · 477 people · 223 sites in 29 countries · Recruiting now